English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsUnichemlaboratories

    Jump to
    • Will continue to pursue inorganic growth in India & US: Torrent Pharma

      Will continue to pursue inorganic growth in India & US: Torrent Pharma

      In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

    • M&A in 2017: Best in a decade

      M&A in 2017: Best in a decade

      The Torrent Pharmaceuticals and Unichem Laboratories deal is close to fruition. On a day this Rs 3600 crore deal has been sealed, it is a good time to look at M&A activity in 2017 so far. In an interview to CNBC-TV18, Raja Lahiri of Grant Thornton, Randhir Kochhar of Ernst & Young, Vivek Gupta of KPMG and Ashvin Parekh of Ashvin Parekh Advisory Services discussed about the same.

    • Torrent to acquire Unichem's domestic branded business for Rs 3,600 crore

      Torrent to acquire Unichem's domestic branded business for Rs 3,600 crore

      Torrent will fund the acquisition through a mix of internal accruals and bank borrowings.

    • No stake sale of India biz; Q2 to be good: Unichem CMD

      No stake sale of India biz; Q2 to be good: Unichem CMD

      Prakash Mody, CMD, Unichem Laboratories expects the second quarter numbers to be good and the company to post double-digit growth in the next couple of quarters.

    • Unichem Labs eyes favourable impact from Re fall; better Q3

      Unichem Labs eyes favourable impact from Re fall; better Q3

      In an interview to CNBC-TV18, Rakesh Parikh, VP-Finance & CFO, Unichem Labs spoke about the company‘s business performance in Q1 of FY14.

    • Unichem Lab gets US FDA green flag for generic drug

      Unichem Lab gets US FDA green flag for generic drug

      Rakesh Parikh, VP-finance of Unichem Laboratories, in an interview on CNBC-TV18 talks about his pharma company receiving approval from the US FDA for a new drug.

    • Unichem Lab's India business to grow in double digit in Q4

      Unichem Lab's India business to grow in double digit in Q4

      In an exclusive interview with CNBC-TV18, Rakesh Parikh CFO of Unichem Laboratories says the company’s Q4 outlook is on the lines of the Q3 growth and the investments made are likely to reap benefits soon. “The India formulation business is continuing in the same as in Q3. We will wrap up the year with double digit growth.”

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347